Skip to main content Skip to search Skip to main navigation

PIC/S: Revised Recommendations on Qualification and Validation

PIC/S has published a fundamentally revised version of its “Recommendations on Qualification and Validation” (PI 006-4). The new document was issued on 30 July 2026, will enter into force on 1 October 2026, and replaces the 2007 edition. The revised document has been expanded from 26 to 49 pages.

The revised recommendations consistently apply a lifecycle and risk-based approach to qualification and validation. They include expanded guidance on quality risk management, data governance and data integrity, change control, performance qualification and ongoing process verification.

The chapters on process validation and cleaning validation have also been extensively updated. PIC/S states that the number of validation batches should be scientifically justified using a risk-based approach and explicitly describes the reference in Annex 15 PIC/S / EU GMP Guide to three consecutive validation batches as a transitional provision. The cleaning validation chapter now provides additional recommendations on HBELs, worst-case selection, manual cleaning and ongoing cleaning verification.

Although PI 006-4 is a recommendation rather than a legally binding GMP requirement, it clearly reflects the current expectations of PIC/S inspectorates. Several topics go beyond the current Annex 15 and may indicate the direction of its ongoing revision.


Source:

PIC/S: Recommendations on Qualification and Validation PI 006-4

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next